Sana Biotechnology's SC291 Gains Fast Track Recognition
Fast Track designation is intended to expedite clinical development and the regulatory review process for new medical therapies. This expedited status plays a crucial role in ensuring that therapies for serious conditions reach patients faster.
Sana Biotechnology, Inc. (NASDAQ: SANA) is proud to announce that the United States Food and Drug Administration (FDA) has granted Fast Track designation for its innovative therapy SC291, targeted at relapsed/refractory systemic lupus erythematosus (SLE). This designation is particularly significant as it addresses an unmet medical need for patients suffering from this debilitating condition.
SC291 is a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy and is being investigated in the GLEAM trial, focusing on patients with B-cell mediated autoimmune diseases, which include not just systemic lupus erythematosus but also lupus nephritis and ANCA-associated vasculitis. Sana Biotechnology is currently in the process of enrolling patients for this critical study and is poised to share initial clinical data in 2025.
Dr. Dhaval Patel, Chief Scientific Officer of Sana, expressed enthusiasm about the Fast Track designation. He stated that this recognition underscores the pressing need for new treatments for patients facing relapsed or refractory SLE. "SC291, as a HIP-modified allogeneic CAR T therapy, promises a scalable manufacturing process capable of producing hundreds of patient doses per run. This positions it to potentially serve as a universal, off-the-shelf therapy to meet this substantial medical need. We eagerly anticipate sharing findings from the ongoing GLEAM trial," he remarked.
The Role of SC291 in Autoimmune Diseases
Developed using Sana's state-of-the-art hypoimmune platform, SC291 stands out as a CD19-directed allogeneic CAR T cell therapy. The approach employs T cells sourced from healthy donors, which are engineered to target CD19—a protein prevalent on the surface of B cells. In various autoimmune diseases, these B cells are central to the disease pathology, and effective therapies targeting them have shown promising results across multiple conditions.
Emerging evidence suggests that achieving deeper depletion of B cells in tissues correlates with improved efficacy and an acceptable safety profile, highlighting the importance of SC291 in advancing treatment options for autoimmune diseases. SC291 aims to introduce a groundbreaking approach where the CAR T cells will actively deplete harmful B cells throughout the body, providing significant therapeutic opportunities.
About Sana Biotechnology
Sana Biotechnology is committed to transforming patient care through the development of engineered cells as medicines. The team at Sana shares a visionary goal of not only repairing and controlling genes but also replacing cells that are missing or damaged. This innovative focus on cell therapy signifies a shift in the treatment landscape for various diseases.
With operations established in multiple locations, including Seattle, WA, and Cambridge, MA, Sana is on a journey to make groundbreaking therapies available to as many patients as possible. To learn more about their efforts and innovations, visit Sana's official website.
Investor Relations Information
For queries or more information about investor relations at Sana, reach out to Nicole Keith via email at investor.relations@sana.com. For media inquiries, you can contact via media@sana.com.
Frequently Asked Questions
What is SC291?
SC291 is an innovative allogeneic CAR T therapy designed to treat B-cell mediated autoimmune diseases, including systemic lupus erythematosus.
Why did SC291 receive Fast Track designation?
The FDA granted Fast Track designation to facilitate the development and expedite the review of drugs that address serious conditions and unmet medical needs.
What is the anticipated timeline for initial data from the GLEAM trial?
Sana Biotechnology expects to report initial clinical data from the GLEAM trial of SC291 in 2025.
How does SC291 work?
SC291 targets CD19 proteins on B cells, which play a pivotal role in autoimmune diseases, aiming for effective depletion throughout the body.
Where is Sana Biotechnology located?
Sana Biotechnology operates in multiple cities, including Seattle, WA, and Cambridge, MA, among others.
